Efficacy of Direct-Acting Antiviral Combination for Patients with Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease

Gastroenterology

Volumn 150, Issue 7, 2016, Pages 1590-1598

  Pockros, Paul J ^a   Reddy, K Rajender ^b   Mantry, Parvez S ^c   Cohen, Eric ^d   Bennett, Michael ^e   Sulkowski, Mark S ^f   Bernstein, David E ^g   Cohen, Daniel E ^d   Shulman, Nancy S ^d   Wang, Deli ^d   Khatri, Amit ^d   Abunimeh, Manal ^d   Podsadecki, Thomas ^d   Lawitz, Eric ^h  

^a SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Liver Instirtue at Methodist Dallas   (United States)

^d ABBVIE INC   (United States)

^e Medical Associates Research Group   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

NS3 4A Protease Inhibitor; NS5A Inhibitor; Renal Disease; RUBY I

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DASABUVIR; ERYTHROPOIETIN; HEMOGLOBIN; INTERLEUKIN 28B; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; RITONAVIR; ABT-267; ABT-333; ABT-450; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND; SULFONAMIDE; URACIL;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FATIGUE; FEMALE; FLANK PAIN; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HEADACHE; HEMODIALYSIS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1 INFECTION; HUMAN; LUNG EDEMA; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; SEVERE RENAL IMPAIRMENT; SIDE EFFECT; TREATMENT INDICATION; TREATMENT WITHDRAWAL; VIROLOGY; VIRUS RESISTANCE; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DOSE RESPONSE; GENETICS; GENOTYPE; HEPACIVIRUS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; SUSTAINED VIROLOGIC RESPONSE;

AGED; ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; KIDNEY FAILURE, CHRONIC; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; RITONAVIR; SULFONAMIDES; SUSTAINED VIROLOGIC RESPONSE; URACIL;

EID: 84966733521     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.02.078     Document Type: Article

References (36)

1. K. Mohd Hanafiah, J. Groeger, A.D. Flaxman, and et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence Hepatology 57 2013 1333 1342
2. Hepatitis C information for health professionals. Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm. Accessed June 2, 2014.
3. G.L. Davis, M.J. Alter, H. El-Serag, and et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 2010 513 521 521 e1-e6
4. E.J. Okoh, J.R. Bucci, J.F. Simon, and et al. HCV in patients with end-stage renal disease Am J Gastroenterol 103 2008 2123 2134
5. S. Bergman, N. Accortt, A. Turner, and et al. Hepatitis C infection is acquired pre-ESRD Am J Kidney Dis 45 2005 684 689
6. M. Jadoul, J.L. Poignet, C. Geddes, and et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study Nephrol Dial Transplant 19 2004 904 909
7. S. Sivapalasingam, S.F. Malak, J.F. Sullivan, and et al. High prevalence of hepatitis C infection among patients receiving hemodialysis at an urban dialysis center Infect Control Hosp Epidemiol 23 2002 319 324
8. F. Fabrizi, B. Takkouche, G. Lunghi, and et al. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies J Viral Hepat 14 2007 697 703
9. J.J. Lee, M.Y. Lin, J.S. Chang, and et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis PLoS One 9 2014 e100790
10. S.K. Satapathy, C.S. Lingisetty, and S. Williams Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection Hepatol Int 6 2012 369 378
11. D.A. Goodkin, J.L. Bragg-Gresham, K.G. Koenig, and et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS) J Am Soc Nephrol 14 2003 3270 3277
12. J.M. Morales, R. Bloom, and D. Roth Kidney transplantation in the patient with hepatitis C virus infection Contrib Nephrol 176 2012 77 86
13. F. Fabrizi, G. Dulai, V. Dixit, and et al. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients Aliment Pharmacol Ther 18 2003 1071 1081
14. M.W. Russo, C.D. Goldsweig, I.M. Jacobson, and et al. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety Am J Gastroenterol 98 2003 1610 1615
15. Rebetol (ribavirin USP) capsules, for oral use [package insert]. Whitehouse Station, NJ: Merck. Revised on May 2015.
16. C. Bunchorntavakul, M. Maneerattanaporn, and D. Chavalitdhamrong Management of patients with hepatitis C infection and renal disease World J Hepatol 7 2015 213 225
17. Copegus (ribavirin) Tablets [package insert]. South San Francisco, CA: Genentech. Revised on August 2011.
18. J.M. Pawlotsky New hepatitis C therapies: the toolbox, strategies, and challenges Gastroenterology 146 2014 1176 1192
19. P. Ferenci Treatment of hepatitis C in difficult-to-treat patients Nat Rev Gastroenterol Hepatol 12 2015 284 292
20. Guidance for Industry Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm225333.pdf. Accessed September 1, 2015.
21. J.J. Feld, K.V. Kowdley, E. Coakley, and et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1594 1603
22. P. Andreone, M.G. Colombo, J.V. Enejosa, and et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection Gastroenterology 147 2014 359 365
23. P. Ferenci, D. Bernstein, J. Lalezari, and et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV N Engl J Med 370 2014 1983 1992
24. F. Poordad, C. Hezode, R. Trinh, and et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis N Engl J Med 370 2014 1973 1982
25. S. Zeuzem, I.M. Jacobson, T. Baykal, and et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1604 1614
26. V. Rustgi, H. Wedemeyer, P. Pockros, and et al. Sustained virologic response rate of 96% in HCV genotype 1a-infected patients treated with ombitasvir/paritaprevir/r and dasabuvir with ribavirin Am J Gastroenterol 110 2015 S862
27. I.M. Jacobson, J.F. Dufour, H. Wedemeyer, and et al. 99.7% sustained virologic response rate in 369 HCV genotype 1b-infected patients treated with label-recommended regimen of ombitasvir/paritaprevir/r and dasabuvir with or without ribavirin Am J Gastroenterol 110 2015 S850 S851
28. A. Khatri, S. Dutta, T.C. Marbury, and et al. The pharmacokinetics and safety of the direct acting antiviral regimen of ABT-450/r, ombitasvir with/without dasabuvir in subjects with mild, moderate and severe renal impairment compared to subjects with normal renal function Hepatology 60 2014 320A
29. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [package insert]. North Chicago, IL: AbbVie, Inc. Revised on October 2015.
30. F. Fabrizi, V. Dixit, and P. Messa Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat 19 2012 601 607
31. S. Petta, M. Maida, F.S. Macaluso, and et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies Gastroenterology 150 2016 145 155.e4
32. D. Roth, D. Nelson, A. Bruchfeld, and et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease Lancet 386 2015 1537 1545
33. Sovaldi (sofosbuvir) tablets, for oral use [package insert]. Foster City, CA: Gilead Sciences. Revised on August 2015.
34. Harvoni (ledipasvir and sofosbuvir) tablets [package insert]. Foster City, CA: Gilead Sciences. Revised on March 2015.
35. S. Ouwerkerk-Mahadevan, M. Beumont-Mauviel, S. Mortier, and et al. Evaluation of the pharmacokinetics and renal excretion of simeprevir in subjects with renal impairment Drugs R D 15 2015 261 270
36. Daklinza (daclatasvir) tablets, for oral use [package insert]. Princeton, NJ: Bristol-Myers Squibb. Revised on July 2015.